LONDON, GREATER LONDON, UK, September 26, 2018 / — The market for organs-on-chips (OOCs), the cell culture chips that imitate the activities, mechanisms and responses of body organs, will be worth $284 million by 2022, according to interviews with industry leaders from The Business Research Company (TBRC) in its report Organ-On-Chip Global Market Opportunities And Strategies To 2021. The market's growth is expected to accelerate going forward. The OOC market is still in the development phase but some commercialized products have established markets. The lung-on-chip market is currently the largest segment, followed by the heart-on-chip market, the liver-on-chip market, the intestine-on-chip market, the kidney-on-chip market, the skin-on-chip market, and the blood-brain barrier-on-chip market.

Organs-on-chips are microfluidic 3D cell culture devices that closely mimic the key physiological functions of body organs. The chips are not designed to biomimic an entire organ, but simulate the physiology of a single functional unit of an organ system. They have resulted from scientific advances in cell biology, microfabrication and microfluidics which allow the emulation of the human micro environment in vitro. This unique feature of OOCs is made possible by integrating biology with advanced engineering technologies. Human organs-on-chips (OOCs) are miniaturized versions of lungs, livers, kidneys, heart, brain, intestines and other vital human organs embedded in a chip.

Download a sample of the report at

North America, particularly the USA, is the largest market for organs-on-chips, followed by Europe. These are the regions where most drug development is currently undertaken. However, Asia and the rest of the world will also see significant growth in the market up to 20212.

Since the organ-on-chip market is still in the research and development phase, and has not been completely commercialized, it is dependent on government grants. For example, in 2012 the USA’s National Institutes of Health (NIH) established a ‘Tissue Chip for Drug Screening’ initiative. The establishment of this program was aided by NIH's Common Fund and the National Institute of Neurological Disorders and Stroke. NIH plans to commit up to $70 million over five years for the program. In total, 15 NIH institutes and centers are assisting in the coordination of this program. Seventeen research projects were awarded about $13 million in July 2012. In 2014, NIH began the second phase of funding for the Tissue Chip for Drug Screening Program in which 11 institutes were supported by $17 million. In September 2017, NIH funded 13 institutions. The funds allocated were close to $15 million.

Request for Discount at

The players in the OOC market are primarily university spinoffs involved in the commercialization of OOC prototypes developed in the universities. These business arms include CN-Bio Innovations, InSphero, Mimetas, TissUse, Hµrel and Nortis.

About The Business Research Company
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Oliver Guirdham
The Business Research Company
+44 207 1930 708
email us here


Powered by WPeMatico